Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 216

1.

Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial.

Gluz O, Kolberg-Liedtke C, Prat A, Christgen M, Gebauer D, Kates R, Paré L, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Kuemmel S, Wuerstlein R, Pelz E, Nitz U, Kreipe HH, Harbeck N.

Int J Cancer. 2019 Jun 4. doi: 10.1002/ijc.32488. [Epub ahead of print]

PMID:
31162838
2.

Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study.

Wuerstlein R, Kates R, Gluz O, Grischke EM, Schem C, Thill M, Hasmueller S, Köhler A, Otremba B, Griesinger F, Schindlbeck C, Trojan A, Otto F, Knauer M, Pusch R, Harbeck N; WSG-PRIMe investigators in Germany, Austria, Switzerland.

Breast Cancer Res Treat. 2019 Jun;175(2):389-399. doi: 10.1007/s10549-018-05075-x. Epub 2019 Feb 22.

3.

West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer.

Nitz U, Gluz O, Clemens M, Malter W, Reimer T, Nuding B, Aktas B, Stefek A, Pollmanns A, Lorenz-Salehi F, Uleer C, Krabisch P, Kuemmel S, Liedtke C, Shak S, Wuerstlein R, Christgen M, Kates RE, Kreipe HH, Harbeck N; West German Study Group PlanB Investigators.

J Clin Oncol. 2019 Apr 1;37(10):799-808. doi: 10.1200/JCO.18.00028. Epub 2019 Feb 20.

PMID:
30785826
4.

Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.

Nitz U, Gluz O, Christgen M, Kates RE, Clemens M, Malter W, Nuding B, Aktas B, Kuemmel S, Reimer T, Stefek A, Lorenz-Salehi F, Krabisch P, Just M, Augustin D, Liedtke C, Chao C, Shak S, Wuerstlein R, Kreipe HH, Harbeck N.

Breast Cancer Res Treat. 2019 May;175(1):265-266. doi: 10.1007/s10549-018-05105-8.

5.

Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results.

Gluz O, Nitz U, Liedtke C, Christgen M, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Bangemann N, Lindner C, Kuemmel S, Clemens M, Potenberg J, Staib P, Kohls A, von Schumann R, Kates R, Kates R, Schumacher J, Wuerstlein R, Kreipe HH, Harbeck N.

J Natl Cancer Inst. 2018 Jun 1;110(6):628-637. doi: 10.1093/jnci/djx258.

PMID:
29228315
6.

Lobular carcinoma in situ and invasive lobular breast cancer are characterized by enhanced expression of transcription factor AP-2β.

Raap M, Gronewold M, Christgen H, Glage S, Bentires-Alj M, Koren S, Derksen PW, Boelens M, Jonkers J, Lehmann U, Feuerhake F, Kuehnle E, Gluz O, Kates R, Nitz U, Harbeck N, Kreipe HH, Christgen M.

Lab Invest. 2018 Jan;98(1):117-129. doi: 10.1038/labinvest.2017.106. Epub 2017 Oct 16.

7.

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel.

Nitz UA, Gluz O, Christgen M, Grischke EM, Augustin D, Kuemmel S, Braun M, Potenberg J, Kohls A, Krauss K, Stefek A, Schumacher C, Forstbauer H, Reimer T, Fischer H, Liedtke C, Wuerstlein R, Schumacher J, Kates R, Kreipe H, Harbeck N; West-German Study Group (WSG)-ADAPT Investigators.

Ann Oncol. 2017 Nov 1;28(11):2768-2772. doi: 10.1093/annonc/mdx494.

PMID:
28945833
8.

Use of single-view digital breast tomosynthesis (DBT) and ultrasound vs. additional views and ultrasound for the assessment of screen-detected abnormalities: German multi-reader study.

Heywang-Köbrunner SH, Hacker A, Jänsch A, Kates R, Wulz-Horber S; German Reader Team.

Acta Radiol. 2018 Jul;59(7):782-788. doi: 10.1177/0284185117732600. Epub 2017 Sep 20.

PMID:
28929783
9.

De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.

Harbeck N, Gluz O, Christgen M, Kates RE, Braun M, Küemmel S, Schumacher C, Potenberg J, Kraemer S, Kleine-Tebbe A, Augustin D, Aktas B, Forstbauer H, Tio J, von Schumann R, Liedtke C, Grischke EM, Schumacher J, Wuerstlein R, Kreipe HH, Nitz UA.

J Clin Oncol. 2017 Sep 10;35(26):3046-3054. doi: 10.1200/JCO.2016.71.9815. Epub 2017 Jul 6.

PMID:
28682681
10.

Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.

Nitz U, Gluz O, Christgen M, Kates RE, Clemens M, Malter W, Nuding B, Aktas B, Kuemmel S, Reimer T, Stefek A, Lorenz-Salehi F, Krabisch P, Just M, Augustin D, Liedtke C, Chao C, Shak S, Wuerstlein R, Kreipe HH, Harbeck N.

Breast Cancer Res Treat. 2017 Oct;165(3):573-583. doi: 10.1007/s10549-017-4358-6. Epub 2017 Jun 29. Erratum in: Breast Cancer Res Treat. 2019 Jan 10;:.

11.

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression.

Nitz U, Gluz O, Huober J, Kreipe HH, Kates RE, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Möbus V, Augustin D, Hoffmann G, Weiss E, Böhmer S, Kreienberg R, Du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Kuhn W.

Ann Oncol. 2017 Nov 1;28(11):2899. doi: 10.1093/annonc/mdw349. No abstract available.

PMID:
27634692
12.

European cost-effectiveness study of uPA/PAI-1 biomarkers to guide adjuvant chemotherapy decisions in breast cancer.

Marguet S, Mazouni C, Ramaekers BL, Dunant A, Kates R, Jacobs VR, Joore MA, Harbeck N, Bonastre J.

Eur J Cancer. 2016 Aug;63:168-79. doi: 10.1016/j.ejca.2016.05.013. Epub 2016 Jun 17.

PMID:
27322916
13.

Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial.

Gluz O, Liedtke C, Huober J, Peyro-Saint-Paul H, Kates RE, Kreipe HH, Hartmann A, Pelz E, Erber R, Mohrmann S, Möbus V, Augustin D, Hoffmann G, Thomssen C, Jänicke F, Kiechle M, Wallwiener D, Kuhn W, Nitz U, Harbeck N; EC-Doc investigators (West German Study Group/AGO-B).

Ann Oncol. 2016 Jun;27(6):1035-40. doi: 10.1093/annonc/mdw070. Epub 2016 Feb 18.

PMID:
27022068
14.

The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer.

Wuerstlein R, Sotlar K, Gluz O, Otremba B, von Schumann R, Witzel I, Schindlbeck C, Janni W, Schem C, Bauerfeind I, Hasmueller S, Tesch H, Paulenz A, Ghali N, Orujov E, Kates RE, Cowens W, Hornberger J, Pelz E, Harbeck N.

Curr Med Res Opin. 2016 Jul;32(7):1217-24. doi: 10.1185/03007995.2016.1166102. Epub 2016 Mar 30.

PMID:
26971372
15.

BRCA1-like profile predicts benefit of tandem high dose epirubicin-cyclophospamide-thiotepa in high risk breast cancer patients randomized in the WSG-AM01 trial.

Schouten PC, Gluz O, Harbeck N, Mohrmann S, Diallo-Danebrock R, Pelz E, Kruizinga J, Velds A, Nieuwland M, Kerkhoven RM, Liedtke C, Frick M, Kates R, Linn SC, Nitz U, Marme F.

Int J Cancer. 2016 Aug 15;139(4):882-9. doi: 10.1002/ijc.30078. Epub 2016 May 5.

16.

West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment.

Gluz O, Nitz UA, Christgen M, Kates RE, Shak S, Clemens M, Kraemer S, Aktas B, Kuemmel S, Reimer T, Kusche M, Heyl V, Lorenz-Salehi F, Just M, Hofmann D, Degenhardt T, Liedtke C, Svedman C, Wuerstlein R, Kreipe HH, Harbeck N.

J Clin Oncol. 2016 Jul 10;34(20):2341-9. doi: 10.1200/JCO.2015.63.5383. Epub 2016 Feb 29.

PMID:
26926676
17.

Impact of guideline-based use of uPA/PAI-1 on patient outcome in intermediate-risk early breast cancer.

Kolben T, Augustin D, Armbrust R, Kolben TM, Degenhardt T, Burgmann M, Goess C, Ditsch N, Kates R, Harbeck N, Wuerstlein R.

Breast Cancer Res Treat. 2016 Jan;155(1):109-15. doi: 10.1007/s10549-015-3653-3. Epub 2015 Dec 7.

PMID:
26643086
18.

Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial.

Erber R, Gluz O, Brünner N, Kreipe HH, Pelz E, Kates R, Bartels A, Huober J, Mohrmann S, Moustafa Z, Liedtke C, Möbus V, Augustin D, Thomssen C, Jänicke F, Kiechle M, Kuhn W, Nitz U, Harbeck N, Hartmann A.

Breast Cancer Res Treat. 2015 Apr;150(2):279-88. doi: 10.1007/s10549-015-3310-x. Epub 2015 Feb 28.

PMID:
25721604
19.

OVSCORE - a validated score to identify ovarian cancer patients not suitable for primary surgery.

Dorn J, Bronger H, Kates R, Slotta-Huspenina J, Schmalfeldt B, Kiechle M, Diamandis EP, Soosaipillai A, Schmitt M, Harbeck N.

Oncol Lett. 2015 Jan;9(1):418-424. Epub 2014 Oct 24.

20.

PTK7 as a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients, and resistance to anthracycline drugs.

Ataseven B, Gunesch A, Eiermann W, Kates RE, Högel B, Knyazev P, Ullrich A, Harbeck N.

Onco Targets Ther. 2014 Oct 6;7:1723-31. doi: 10.2147/OTT.S62676. eCollection 2014.

21.

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression.

Nitz U, Gluz O, Huober J, Kreipe HH, Kates RE, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Möbus V, Augustin D, Hoffmann G, Weiss E, Böhmer S, Kreienberg R, Du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Kuhn W.

Ann Oncol. 2014 Aug;25(8):1551-7. doi: 10.1093/annonc/mdu186. Epub 2014 May 14. Erratum in: Ann Oncol. 2017 Nov 1;28(11):2899.

PMID:
24827128
22.

Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer.

Nitz U, Gluz O, Zuna I, Oberhoff C, Reimer T, Schumacher C, Hackmann J, Warm M, Uleer C, Runde V, Dünnebacke J, Belzl N, Augustin D, Kates RE, Harbeck N; West German Study Group.

Ann Oncol. 2014 Jan;25(1):75-80. doi: 10.1093/annonc/mdt505.

PMID:
24356620
23.

PTK7 expression in triple-negative breast cancer.

Ataseven B, Angerer R, Kates R, Gunesch A, Knyazev P, Högel B, Becker C, Eiermann W, Harbeck N.

Anticancer Res. 2013 Sep;33(9):3759-63.

PMID:
24023307
25.

Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancer.

Jacobs VR, Kates RE, Kantelhardt E, Vetter M, Wuerstlein R, Fischer T, Schmitt M, Jaenicke F, Untch M, Thomssen C, Harbeck N.

Breast Cancer Res Treat. 2013 Apr;138(3):839-50. doi: 10.1007/s10549-013-2496-z. Epub 2013 Apr 9.

PMID:
23568480
26.

Transformational adaptation when incremental adaptations to climate change are insufficient.

Kates RW, Travis WR, Wilbanks TJ.

Proc Natl Acad Sci U S A. 2012 May 8;109(19):7156-61. doi: 10.1073/pnas.1115521109. Epub 2012 Apr 16.

27.

What kind of a science is sustainability science?

Kates RW.

Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):19449-50. doi: 10.1073/pnas.1116097108. Epub 2011 Nov 23. No abstract available.

28.

3D breast ultrasound: a significant predictor in breast cancer reduction under pre-operative chemotherapy.

Warm M, Duda V, Eichler C, Harbeck N, Gossmann A, Thomas A, Hoopmann M, Ohlinger R, Breidenbach M, Kates RE.

Anticancer Res. 2011 Nov;31(11):4039-42.

PMID:
22110239
29.

Injury risk to specific body regions of pedestrians in frontal vehicle crashes modeled by empirical, in-depth accident data.

Helmer T, Ebner A, Samaha RR, Scullion P, Kates R.

Stapp Car Crash J. 2010 Nov;54:93-117.

PMID:
21512905
30.

Tumor angiogenesis as prognostic and predictive marker for chemotherapy dose-intensification efficacy in high-risk breast cancer patients within the WSG AM-01 trial.

Gluz O, Wild P, Liedtke C, Kates R, Mendrik H, Ehm E, Artinger V, Diallo-Danebrock R, Ting E, Mohrmann S, Poremba C, Harbeck N, Nitz U, Hartmann A, Gaumann A.

Breast Cancer Res Treat. 2011 Apr;126(3):643-51. doi: 10.1007/s10549-011-1377-6. Epub 2011 Feb 12.

PMID:
21318601
31.

Impact of tumor biology, particularly triple-negative status, on response to pre-operative sequential, dose-dense epirubicin, cyclophosphamide followed by docetaxel in breast cancer.

Warm M, Kates R, Grosse-Onnebrink E, Stoff-Khalili M, Hoopmann M, Mallmann P, Thomas A, Harbeck N.

Anticancer Res. 2010 Oct;30(10):4251-9.

PMID:
21036749
32.

Benefits of early and prolonged fulvestrant treatment in 848 postmenopausal advanced breast cancer patients.

Warm M, Kates R, Overkamp F, Thomas A, Harbeck N.

Breast Cancer Res Treat. 2011 Jan;125(1):127-36. doi: 10.1007/s10549-010-1214-3. Epub 2010 Oct 20.

PMID:
20960229
33.

Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer.

Dorn J, Harbeck N, Kates R, Gkazepis A, Scorilas A, Soosaipillai A, Diamandis E, Kiechle M, Schmalfeldt B, Schmitt M.

Ann Oncol. 2011 Apr;22(4):877-83. doi: 10.1093/annonc/mdq462. Epub 2010 Oct 5.

PMID:
20924077
34.

Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open-label clinical trial.

Friedman DM, Llanos C, Izmirly PM, Brock B, Byron J, Copel J, Cummiskey K, Dooley MA, Foley J, Graves C, Hendershott C, Kates R, Komissarova EV, Miller M, Paré E, Phoon CK, Prosen T, Reisner D, Ruderman E, Samuels P, Yu JK, Kim MY, Buyon JP.

Arthritis Rheum. 2010 Apr;62(4):1138-46. doi: 10.1002/art.27308.

35.

Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy.

Gluz O, Mengele K, Schmitt M, Kates R, Diallo-Danebrock R, Neff F, Royer HD, Eckstein N, Mohrmann S, Ting E, Kiechle M, Poremba C, Nitz U, Harbeck N.

J Clin Oncol. 2009 Dec 20;27(36):6144-51. doi: 10.1200/JCO.2008.19.6261. Epub 2009 Nov 9.

PMID:
19901122
36.

Avoiding spam in the proteolytic internet: future strategies for anti-metastatic MMP inhibition.

Krüger A, Kates RE, Edwards DR.

Biochim Biophys Acta. 2010 Jan;1803(1):95-102. doi: 10.1016/j.bbamcr.2009.09.016. Epub 2009 Oct 1. Review.

37.

Side-effects of pre-operative epirubicin-paclitaxel therapy in primary breast cancer associated with tumor biology.

Warm M, Kates R, Thomas A, Fischer T, Harbeck N.

Anticancer Res. 2009 Jul;29(7):2675-80.

38.

Optimized pro-active management of anemia by Epoetin alpha in pre-operative chemotherapy for primary breast cancer.

Warm M, Kates R, Dick M, Thomas A, Mallmann P, Hoopmann M, Harbeck N.

Oncol Rep. 2009 Mar;21(3):777-85.

PMID:
19212639
39.

Postoperative sense of well-being and quality of life in breast cancer patients do not depend on type of primary surgery.

Warm M, Gatermann C, Kates R, Mallmann P, Paepke S, Harbeck N, Thomas A.

Onkologie. 2008 Mar;31(3):99-104. doi: 10.1159/000113540. Epub 2008 Feb 8.

PMID:
18322412
40.

Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial.

Gluz O, Nitz UA, Harbeck N, Ting E, Kates R, Herr A, Lindemann W, Jackisch C, Berdel WE, Kirchner H, Metzner B, Werner F, Schütt G, Frick M, Poremba C, Diallo-Danebrock R, Mohrmann S; West German Study Group.

Ann Oncol. 2008 May;19(5):861-70. doi: 10.1093/annonc/mdm551. Epub 2008 Jan 3.

PMID:
18174609
41.

African poverty: a grand challenge for sustainability science.

Kates RW, Dasgupta P.

Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):16747-50. Epub 2007 Oct 17. No abstract available.

42.

Improvement of safety profile of docetaxel by weekly administration in patients with metastatic breast cancer.

Warm M, Nawroth F, Ohlinger R, Valter M, Pantke E, Mallmann P, Harbeck N, Kates R, Thomas A.

Onkologie. 2007 Sep;30(8-9):436-41. Epub 2007 Sep 7.

PMID:
17848815
43.

DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.

Maier S, Nimmrich I, Koenig T, Eppenberger-Castori S, Bohlmann I, Paradiso A, Spyratos F, Thomssen C, Mueller V, Nährig J, Schittulli F, Kates R, Lesche R, Schwope I, Kluth A, Marx A, Martens JW, Foekens JA, Schmitt M, Harbeck N; European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.

Eur J Cancer. 2007 Jul;43(11):1679-86. Epub 2007 Jun 29.

PMID:
17601725
44.

Impact of tumor biological factors on response to pre-operative epirubicin and paclitaxel chemotherapy in primary breast cancer.

Warm M, Kates R, Mallmann P, Dick M, Nawroth F, Harbeck N, Paepke S, Thomas A.

Anticancer Res. 2007 Mar-Apr;27(2):1031-8.

45.
46.

Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patients.

Dorn J, Schmitt M, Kates R, Schmalfeldt B, Kiechle M, Scorilas A, Diamandis EP, Harbeck N.

Clin Cancer Res. 2007 Mar 15;13(6):1742-8.

47.

Analysis of specific transcriptional regulators as early predictors of independent prognostic relevance in resected colorectal cancer.

Maurer GD, Leupold JH, Schewe DM, Biller T, Kates RE, Hornung HM, Lau-Werner U, Post S, Allgayer H.

Clin Cancer Res. 2007 Feb 15;13(4):1123-32.

48.

Reconstruction of New Orleans after Hurricane Katrina: a research perspective.

Kates RW, Colten CE, Laska S, Leatherman SP.

Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14653-60. Epub 2006 Sep 26.

49.

Intraoperative assessment of mitral regurgitation: role of phenylephrine challenge.

Mihalatos DG, Gopal AS, Kates R, Toole RS, Bercow NR, Lamendola C, Berkay SH, Damus P, Robinson N, Grimson R, Shen K, Reichek N.

J Am Soc Echocardiogr. 2006 Sep;19(9):1158-64.

PMID:
16950471
50.

Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma.

Dorn J, Harbeck N, Kates R, Magdolen V, Grass L, Soosaipillai A, Schmalfeldt B, Diamandis EP, Schmitt M.

Biol Chem. 2006 Aug;387(8):1121-8.

PMID:
16895483

Supplemental Content

Support Center